Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

686 ARTÍCULOS , VIENDO DEL 646 AL 660

Emerging drugs for dementia with Lewy Bodies: a review of Phase II & III trials

Tolea MI, Ezzeddine R, Camacho S, Galvin JE.

Expert Opin Emerg Drugs. 2023 Dec;28(3):167-180. doi: 10.1080/14728214.2023.2244425. Epub 2023 Aug 8.

A case of exploding head syndrome preceding the onset of mild cognitive impairment with Lewy bodies

Kitagawa S, Okamoto N, Ikenouchi A, Igata R, Hashimoto R, Konishi Y, Tesen H, Yoshimura R.

Psychogeriatrics. 2023 Mar;23(2):368-370. doi: 10.1111/psyg.12938. Epub 2023 Jan 27.

Metals linked with the most prevalent primary neurodegenerative dementias in the elderly: A narrative review

Mateo D, Marquès M, Torrente M.

Environ Res. 2023 Nov 1;236(Pt 1):116722. doi: 10.1016/j.envres.2023.116722. Epub 2023 Jul 23.

Iron and Ferroptosis More than a Suspect: Beyond the Most Common Mechanisms of Neurodegeneration for New Therapeutic Approaches to Cognitive Decline and Dementia

Cerasuolo M, Di Meo I, Auriemma MC, Trojsi F, Maiorino MI, Cirillo M, Esposito F, Polito R, Colangelo AM, Paolisso G, Papa M, Rizzo MR.

Int J Mol Sci. 2023 Jun 1;24(11):9637. doi: 10.3390/ijms24119637.

Pathogenesis of miR-155 on nonmodifiable and modifiable risk factors in Alzheimer's disease

Liu JJ, Long YF, Xu P, Guo HD, Cui GH.

Alzheimers Res Ther. 2023 Jul 14;15(1):122. doi: 10.1186/s13195-023-01264-z.

Relative Risks for Dementia among Individuals with Glaucoma: A Meta-Analysis of Observational Cohort Studies

Huh MG, Kim YK, Lee J, Shin YI, Lee YJ, Choe S, Kim DW, Jeong Y, Jeoung JW, Park KH.

Korean J Ophthalmol. 2023 Dec;37(6):490-500. doi: 10.3341/kjo.2023.0059. Epub 2023 Oct 25.

Neurons, Nose, and Neurodegenerative Diseases: Olfactory Function and Cognitive Impairment

Fatuzzo I, Niccolini GF, Zoccali F, Cavalcanti L, Bellizzi MG, Riccardi G, de Vincentiis M, Fiore M, Petrella C, Minni A, Barbato C.

Int J Mol Sci. 2023 Jan 20;24(3):2117. doi: 10.3390/ijms24032117.

Use of cannabidiol (CBD) for the treatment of cognitive impairment in psychiatric and neurological illness: A narrative review

Ortiz R, Rueda S, Di Ciano P.

Exp Clin Psychopharmacol. 2023 Oct;31(5):978-988. doi: 10.1037/pha0000659. Epub 2023 May 1.

Task-Evoked Pupillary Response as a Potential Biomarker of Dementia and Mild Cognitive Impairment: A Scoping Review

Zeeman M, Figeys M, Brimmo T, Burnstad C, Hao J, Kim ES.

Am J Alzheimers Dis Other Demen. 2023 Jan-Dec;38:15333175231160010. doi: 10.1177/15333175231160010.

Speech and language markers of neurodegeneration: a call for global equity

García AM, de Leon J, Tee BL, Blasi DE, Gorno-Tempini ML.

Brain. 2023 Dec 1;146(12):4870-4879. doi: 10.1093/brain/awad253.

Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis

d'Angremont E, Begemann MJH, van Laar T, Sommer IEC.

JAMA Neurol. 2023 Aug 1;80(8):813-823. doi: 10.1001/jamaneurol.2023.1835.

Neuropsychological domains and fitness to drive in mild cognitive impairment or Alzheimer's disease

Quintas JL, Trindade IOA, Gameiro KSD, Pitta LSR, Camargos EF, Nóbrega OT.

Accid Anal Prev. 2023 Oct;191:107188. doi: 10.1016/j.aap.2023.107188. Epub 2023 Jul 7.

[The exposome in the context of preventive measures for Alzheimer's and Parkinson's diseases]

Schäffer E, Piel J.

Nervenarzt. 2023 Oct;94(10):892-903. doi: 10.1007/s00115-023-01538-9. Epub 2023 Aug 28.

White matter hyperintensities in cognitive impairment with Lewy body disease: a multicentre study

Gan J, Shi Z, Liu S, Li X, Liu Y, Zhu H, Shen L, Zhang G, Lu H, Gang B, Chen Z, Ji Y.

Eur J Neurol. 2023 Dec;30(12):3711-3721. doi: 10.1111/ene.16002. Epub 2023 Aug 7.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias